Neratinib maleate monohydrate is an oral cancer medication used for the extended adjuvant treatment of early-stage HER2-positive breast cancer after trastuzumab therapy. It works by irreversibly blocking HER1, HER2, and HER4 receptors to prevent cancer cell growth. It is taken daily with food, and common side effects include diarrhea, nausea, and fatigue. It is grouped under the following drug class(es): Kinase inhibitors. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include 2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-, (2Z)-2-butenedioate and hydrate (1:1:1). Its PubChem CID is 25267298.
Neratinib maleate monohydrate
| CAS No | 1144516-12-0 |
|---|---|
| Molecular Formula | C34H35ClN6O8 |
| Molecular Weight | 691.1 g/mol |
| Synonyms | (Z)-but-2-enedioic acid;(E)-N-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide;hydrate |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Neratinib maleate monohydrate is an oral cancer medication used for the extended adjuvant treatment of early-stage HER2-positive breast cancer after trastuzumab therapy.
The listed CAS number is 1144516-12-0.
The listed molecular formula is C34H35ClN6O8.
The listed molecular weight is 691.1 g/mol.
(Z)-but-2-enedioic acid;(E)-N-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide;hydrate.
The source lists 2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-, (2Z)-2-butenedioate and hydrate (1:1:1).